Imagine revolutionizing skin care for chronic conditions without the fear of overwhelming side effects – but is this innovative twist in dermatology coming at a hidden cost?
Dive into this fascinating discussion with Gabriela Maloney, DO, who shared her insights at the SDPA Fall Conference on using JAK inhibitors off-label for dermatology patients. It's a game-changer for those battling tough skin issues, and we're about to unpack why. But here's where it gets controversial – are we pushing boundaries with drugs not officially approved for these uses, or unlocking safer paths to relief?
In her talk, Dr. Maloney pointed out the frustrations dermatologists face with traditional immunosuppressants. These medications often demand relentless lab tests to monitor for complications, come with a laundry list of drug interactions, and can cause unwanted side effects that leave patients feeling improved but far from fully healed. 'We're often giving them immunosuppressants that require a lot of lab monitoring, a lot of drug interactions, a lot of potential side effects, and they're making people feel slightly better, but not completely clear,' she explained. For beginners, think of these as broad-spectrum solutions that might calm a storm but don't always clear the skies – they suppress the immune system broadly, risking infections or other problems.
That's where JAK inhibitors enter the scene, targeting the JAK-STAT pathway – a key player in many inflammatory skin conditions. Dr. Maloney highlighted the excitement: 'We know that the inflammatory pathway of those conditions involves the JAK-STAT pathway, which is really awesome, because we have great drugs that we can now use. Not only are we able to achieve clearance in levels that we were not able to do before, but we're also able to do it safely.'
To clarify for those new to this, the JAK-STAT pathway is like a cellular communication highway that ramps up inflammation in diseases like psoriasis or eczema. JAK inhibitors act like volume controls, gently turning down the noise without shutting off the whole system. As Dr. Maloney described, 'By inhibiting JAKs, we're really kind of toning down the volume of inflammation, but in a very targeted way. We're not wiping out the immune system. We're not depleting their white cells, T cells, or B cells. We really are just dialing down that volume knob a little bit lower.' This targeted approach means patients often see clearer skin and fewer risks, offering a breath of fresh air compared to older treatments.
And this is the part most people miss – the FDA has greenlit several JAK inhibitors in recent years, including upadacitinib, baricitinib, abrocitinib, and deucravacitinib, primarily for conditions like rheumatoid arthritis or certain dermatoses. During her presentation, Dr. Maloney walked attendees through the drugs' mechanisms of action and practical strategies for integrating them into care for various inflammatory disorders. It's not just theory; real-world applications are showing promise, with patients achieving remissions that were once out of reach.
But here's where it gets intriguing – and potentially divisive. Dr. Maloney discussed off-label explorations, like in vitiligo (where skin loses pigment) or hidradenitis suppurativa (painful boils under the skin), two ailments with limited treatment options. 'I mean, there are a lot of drugs that are on phase 3 and 2 trials for vitiligo and for hidradenitis suppurativa, two chronic conditions that we really don't have great medications for,' she noted. She also touched on bullous diseases such as bullous pemphigoid and pemphigus vulgaris, as well as erosive lichen planus and cicatricial alopecia – a scarring form of hair loss.
While JAK inhibitors are approved for alopecia areata (patchy hair loss), they're not yet cleared for cicatricial alopecia. Yet, Dr. Maloney shared promising findings on overlapping inflammatory pathways, with some patients experiencing hair regrowth in cicatricial cases. This hints at shared root causes across conditions, potentially broadening treatment horizons. For example, imagine a patient with vitiligo also dealing with inflammatory flares – a JAK inhibitor might address both by targeting that common pathway, reducing the need for multiple medications.
Of course, off-label use sparks debate. Is it ethical to prescribe unapproved drugs, even if trials show benefits? Critics might argue it's risky experimentation on patients, while proponents see it as compassionate care filling treatment gaps. Dr. Maloney emphasized safety, but what if long-term effects emerge? And this is the point that could fuel heated discussions – are we undervaluing the immune system's role by fine-tuning it so precisely, potentially leaving patients vulnerable to other issues?
To explore more dermatology topics from the 2025 SDPA Fall Conference, check out our site's latest coverage. (Note: Quotes in this summary have been lightly edited for clarity.)
References
Incyte Announces Additional FDA Approval of Opzelura® (Ruxolitinib) Cream in Children Ages 2-11 with Atopic Dermatitis. Incyte. September 18, 2025. Accessed November 8, 2025. https://investor.incyte.com/news-releases/news-release-details/incyte-announces-additional-fda-approval-opzelurar-ruxolitinib.
Maloney G. Off-Label Usage of JAK Inhibitors. Presented at the Society of Dermatology Physician Associates (SDPA) Fall Conference, November 5-9, San Antonio, TX.
Newsletter
Stay ahead with thousands of other clinicians by subscribing to HCPLive for the latest on therapies, trial results, and expert perspectives.
What do you think? Do you view off-label JAK inhibitor use as a bold step forward in dermatology, or is it too risky without full approvals? Have you seen similar debates in your practice? Share your thoughts in the comments below – I'd love to hear differing views to spark a meaningful conversation!
